LabTurbo Biotech Corporation (7725) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of LabTurbo Biotech Corporation TWD 4.60, price TWD 22.35, upside -79.4%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch LabTurbo Biotech Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
LabTurbo Biotech Corporation engages in the research, manufacture, and sale of gene detection systems and kits in Taiwan, the United States, the Czech Republic, Spain, France, Israel, Singapore, the Philippines, and Malaysia. It serves hospitals. The company was founded in 2000 and is based in Taipei, Taiwan.
Stock analysis
LabTurbo Biotech Corporation (7725) currently trades at 22.35 TWD, while our model-based Fair Value estimate is 4.60 TWD, implying the stock looks roughly 385.9% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 18.36 TWD per share, and 0 of the 10 models we run sit above the 22.35 TWD price.
Bear case: the Earnings-Based group reads lowest at 2.25 TWD, and 10 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: 4.15 TWD (bear) to 5.84 TWD (bull), the price of 22.35 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
LabTurbo Biotech Corporation reported revenue of 73.0M TWD in FY2024 versus 979M TWD in FY2021, a compound −57.9%/yr. Reported net income was 13.0M TWD in FY2024, compounding −69.5%/yr from FY2021.
Key figures
Market cap 1.1B TWD (≈ $34.0M) · EPS (TTM) −2.74 TWD · Net margin 17.8% · Return on assets (EBIT) 15.5% · Free cash flow −140M TWD · Net cash 147M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −79%, 7725 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (2.25 TWD to 18.36 TWD). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 4.15 TWDFair Value 4.60 TWDBull 5.84 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−61.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−57.9%
’21
’22
’23
’24
What shareholders gained per year (last 3 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−71.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−71.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.60% → −250%
Compare LabTurbo Biotech Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−79% · Bottom 25%
Profitability
Return on assets0% · Above median
Net margin (TTM)18% · Above median
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Dividend yield (TTM)0.0% · Bottom 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is LabTurbo Biotech Corporation (7725) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4.60 TWD versus a price of 22.35 TWD, about −79% upside (overvalued).
What is the fair value of 7725?
Our model-based fair value for LabTurbo Biotech Corporation is 4.60 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 22.35 TWD.
What is the quality score of 7725?
LabTurbo Biotech Corporation has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LabTurbo Biotech Corporation (7725)?
Our model-based price target is the fair value of 4.60 TWD (as of Sep 24, 2026) from 10 valuation models. Cautious scenario 4.15 TWD, optimistic scenario 5.84 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the LabTurbo Biotech Corporation stock forecast for 2026?
Our models put fair value at 4.60 TWD, about −79% upside versus a price of 22.35 TWD (overvalued). Cautious scenario 4.15 TWD, optimistic scenario 5.84 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of LabTurbo Biotech Corporation (7725)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LabTurbo Biotech Corporation it is 4.60 TWD per share (as of Sep 24, 2026), against a price of 22.35 TWD. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is LabTurbo Biotech Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 7725 trades above its calculated fair value: price 22.35 TWD, fair value 4.60 TWD, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7725?
No. The price is what the market pays today (22.35 TWD); the fair value is what the company's own numbers justify (4.60 TWD). For LabTurbo Biotech Corporation the two are 17.75 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is LabTurbo Biotech Corporation worth?
The market values LabTurbo Biotech Corporation at about 1.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 22.35 TWD; our models calculate a fair value of 4.60 TWD per share.
What do the bullish and bearish scenarios say about 7725?
Our models span a range for LabTurbo Biotech Corporation: cautious scenario 4.15 TWD, base 4.60 TWD, optimistic 5.84 TWD per share (as of Sep 24, 2026, price 22.35 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 7725 from its 52-week high?
LabTurbo Biotech Corporation trades at 22.35 TWD, about 13% below its 52-week high of 25.78 TWD and 9% above the low of 20.58 TWD (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4.60 TWD is for.
Which stocks are comparable to LabTurbo Biotech Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LabTurbo Biotech Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 22.35 TWD, calculated fair value 4.60 TWD (−79%), Quality Score 48/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7725 calculated?
We run LabTurbo Biotech Corporation through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.60 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. LabTurbo Biotech Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LabTurbo Biotech Corporation (7725)?
The closing price on Sep 23, 2026 was 22.35 TWD. Our model-based fair value is 4.60 TWD, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LabTurbo Biotech Corporation right now?
The price sits above even our optimistic bull case (5.84 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of LabTurbo Biotech Corporation
How large is the market capitalisation of LabTurbo Biotech Corporation (7725)?
The market capitalisation of LabTurbo Biotech Corporation is 1.1B TWD (≈ $34.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of LabTurbo Biotech Corporation (7725)?
Earnings per share at LabTurbo Biotech Corporation are −2.74 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of LabTurbo Biotech Corporation (7725)?
The net margin of LabTurbo Biotech Corporation is 17.8% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of LabTurbo Biotech Corporation (7725)?
On an EBIT basis the return on assets of LabTurbo Biotech Corporation is 15.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does LabTurbo Biotech Corporation (7725) generate?
The free cash flow of LabTurbo Biotech Corporation is −140M TWD (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does LabTurbo Biotech Corporation (7725) hold?
LabTurbo Biotech Corporation holds more cash than debt, 147M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch LabTurbo Biotech Corporation in the live analysis
One click puts LabTurbo Biotech Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
